Suppr超能文献

核输出选择性抑制剂(SINE)——一类新型抗癌药物。

Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.

作者信息

Parikh Kaushal, Cang Shundong, Sekhri Arunabh, Liu Delong

机构信息

Henan Tumor Hospital, Zhengzhou University, Zhengzhou, China.

出版信息

J Hematol Oncol. 2014 Oct 15;7:78. doi: 10.1186/s13045-014-0078-0.

Abstract

Dysregulation of the nucleo-cytoplasmic transport of proteins plays an important role in carcinogenesis. The nuclear export of proteins depends on the activity of transport proteins, exportins. Exportins belong to the karyopherin β superfamily. Exportin-1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), mediates transport of around 220 proteins. In this review, we summarized the development of a new class of antitumor drugs, collectively known as selective inhibitors of nuclear export (SINE). KPT-330 (selinexor) as an oral agent is showing activities in early clinical trials in both solid tumors and hematological malignancies.

摘要

蛋白质核质运输失调在肿瘤发生过程中起重要作用。蛋白质的核输出取决于运输蛋白即输出蛋白的活性。输出蛋白属于核转运蛋白β超家族。输出蛋白1(XPO1),也称为染色体区域维持蛋白1(CRM1),介导约220种蛋白质的运输。在本综述中,我们总结了一类新型抗肿瘤药物的发展,这类药物统称为核输出选择性抑制剂(SINE)。KPT-330(塞利尼索)作为一种口服药物,在实体瘤和血液系统恶性肿瘤的早期临床试验中均显示出活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda8/4200201/4de9873034f1/13045_2014_Article_78_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验